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cal disease in Singapore and Hong Kong from a payer perspective. METHODS: A 
decision-analytic model was developed to estimate the impact of vaccination with 
PCV13 relative to PCV7 and to PCV10 on invasive pneumococcal disease (IPD), 
pneumonia, and otitis media. Model inputs include disease incidence, sequelae, and 
mortality; serotype coverage; immunogenicity; direct and indirect effects; and costs. 
Speciﬁc local data were obtained from regional surveillance and published literature. 
Where local data were unavailable, proxy data were derived from published US 
sources. Vaccine costs assumed price parity to the private market unit price for PCV7 
and were based on a four dose schedule. Costs and outcomes were discounted at 3%. 
RESULTS: Preliminary results demonstrated that PCV13 was dominant compared to 
PCV10 and compared to PCV7, both with and without indirect effects, in Singapore 
and in Hong Kong. The net cost savings per child vaccinated with PCV13 compared 
to PCV7 was S$7 in Singapore and HK$1352 in Hong Kong when including indirect 
effects. With direct effects only, the net cost savings per child vaccinated was S$1 and 
HK$4 in the respective countries. PCV13 direct effects would reduce IPD by 86% 
amongst vaccinated children in both regions. Results also indicated further reductions 
in pneumonia and otitis media burden with PCV13. CONCLUSIONS: These prelimi-
nary results suggest that pediatric national immunization programs with PCV13 in 
Singapore and in Hong Kong are expected to substantially decrease pneumococcal 
illness. In addition, the programs are expected to be cost-savings relative to PCV10 
and to PCV7.
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OBJECTIVES: Determine cost-effectiveness and cost-utility of three treatment schemes 
(based on lopinavir [LPV/r], darunavir [DRV/r] and atazanavir [ATZ/r]) used in 
patients with HIV/AIDS after a ﬁrst virological failure, in Colombia. METHODS: We 
designed a Markov model with 10 six-month cycles (5-year timeframe) based on 
efﬁcacy measures obtained from published clinical trials. We estimated local direct 
costs from a payer perspective using 2009 ofﬁcial rates for drugs and lab tests, and 
real costs for AIDS-related complications (exchange rate Col$1968 per US$, January 
2010). Utilities (in QALYs) were obtained from the Tufts CEA registry. Effectiveness 
was measured as further virological failures, need of “rescue therapy”, AIDS-related 
complications, and deaths per 1000 patients (estimated through Monte Carlo proba-
bilistic simulation). We applied a 5% discount rate for costs and QALYs. RESULTS: 
Average cost per patient was US$ 39,334 for DRV/r, US$ 41,825 for LPV/r and US$ 
49,135 for ATZ/r. Five-year mortality was 5.9% in the DRV/r group, 7.6% for LPV/r 
and 8.0% for ATZ/r; there were 235 AIDS-related complications in the DRV/r group, 
383 in the LPV/r group and 326 in ATZ/r. Rescue therapy was required in 85 occa-
sions in the DRV/r group, 273 in the LPV/r group and 198 in the ATZ/r group, while 
there were 700 virological failures per 1000 patients in the DRV/r group, 1070 in 
LPV/r and 1080 in ATZ/r. Average QALYs gained in the ﬁve-year period were: DRV/r 
3.92; LPV/r 3.81 and ATZ/r 3.84. Cost-utility and cost-effectiveness analysis show 
darunavir as the dominant alternative since the ﬁrst year compared to atazanavir, and 
since the fourth year compared to lopinavir. One way sensitivity analyses did not 
modify the results signiﬁcantly. CONCLUSIONS: In Colombia, initial treatment with 
darunavir in patients with a ﬁrst antiretroviral therapy failure is less costly than with 
lopinavir or atazanavir and is signiﬁcantly more effective.
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OBJECTIVES: To evaluate the cost-effectiveness of 2009 pandemic inﬂuenza 
A(H1N1) (pH1N1) vaccination in various age and risk groups in the United States. 
METHODS: A computer simulation model was developed to predict costs and health 
outcomes for a pH1N1 vaccination program using inactivated vaccine compared to 
no vaccination. The modeled target population included hypothetical cohorts of 
persons aged 6 months and older stratiﬁed by age and risk. Probabilities, costs and 
quality-of-life weights were derived from emerging primary data on pH1N1 infections 
in the US, published and unpublished data for seasonal and pH1N1 illnesses, supple-
mented by expert opinion. The analysis used a one-year time horizon for most end-
points but also included longer-term costs and consequences of long-term sequelae 
and deaths. A societal perspective was used. The main endpoint was the incremental 
cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensi-
tivity analyses were conducted to evaluate the robustness of results as parameters were 
varied over plausible ranges, including a scenario analysis to evaluate the effect of 
timing of vaccination assuming a hypothetical 16-week ﬂu season and normalized 
epidemic curve of illness. RESULTS: For vaccination initiated prior to the outbreak, 
pH1N1 vaccination was cost-saving for persons 6 months to 64 years with high risk 
conditions assuming a 15% overall attack rate. For those without high risk conditions, 
pH1N1 vaccination was not cost-saving but required a net investment; cost-effective-
ness ratios ranged from $8,000-$52,000/QALY depending on age and risk category. 
Results were sensitive to the number of vaccine doses needed, costs of vaccination, 
illness rates, and timing of vaccine delivery. Cost-effectiveness ratios increased sub-
stantially if vaccination were initiated after the 10th week of the start of a hypothetical 
16-week epidemic. CONCLUSIONS: Vaccination for pH1N1 for children and work-
ing-age adults is cost-effective compared to other preventive health interventions under 
a wide range of scenarios.
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OBJECTIVES: To evaluate the clinical-economic value of caspofungin therapy vs. 
standard and alternative treatments in patients with invasive candidiasis (IC) hospital-
ized in intensive care units (ICU). METHODS: The pharmacoeconomic analysis uti-
lized the cost-effectiveness analysis (CER). If the efﬁcacy and the cost of any of the 
studied regimens exceeded those of the other regimen, an incremental analysis was 
carried out (ICERs). A list of direct costs was compiled: clinical laboratory procedures 
carried out at invasive candidiasis diagnosis; antimycotic costs in the treatment of 
invasive candidiasis; antimycotic administration costs; costs of the diagnosis of adverse 
events following administration of an antimycotic. Efﬁcacy and safety data were based 
on additional analyses of a randomised, double blind, multinational trial of antimycot-
ics. To evaluate the degree of inaccuracy of the results, sensitivity analyses were 
performed RESULTS: It was established that the mode of starting treatment of IC 
amphotericin B and then caspofungin was both more effective and less expensive in 
comparison with the use of amphotericin B and then amphotericin B lipid complex. 
When we used caspofungin or amphotericin B lipid complex shares of expenses on 
antimycotices were 80–87%. Lower parameters are received at application ampho-
tericin B and ﬂuconazole, 46 % and 66 %, accordingly. The analysis of the alternative, 
whose efﬁciency of treatment of IC was equal in all groups, has shown, that the least 
expensive strategy was that where the starting therapy was amphotericin B. The 
unilateral analysis of sensitivity proves that the efﬁciency of expenses of the treatment 
of IC was more sensitive to a parameter of efﬁciency than to the change of the expenses 
connected with the price of medicines. CONCLUSIONS: In modern Russian condi-
tions, in view of a high level of resistance in vitro Candida spp. to ﬂuconazole and 
high toxicity of amphotericin B, the most expedient strategy is that starting what the 
application of caspofungin.
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OBJECTIVES: Candida species are a common cause of nosocomial bloodstream 
infection. Positive blood cultures or high clinical suspicion for candidemia prompt 
empiric antifungal therapy. Early species identiﬁcation allows earlier initiation of 
appropriate therapy or de-escalation to less expensive narrow spectrum therapy. Our 
institute used Candida PNA-FISH (Test A) to rapidly differentiate Candida albicans 
from non-albicans species. Two newer tests can differentiate among albicans, glabrata 
or others (Candida PNA-FISH dual probe, Test B) and among albicans/parapsilosis, 
tropicalis, glabrata/krusei or others (Candida PNA-FISH Trafﬁc Light, Test C). This 
study aimed to predict cost impacts if newer tests would have been used. METHODS: 
From a hospital administration perspective, a retrospective chart review of candidemic 
patients between January 2007 and May 2008 was conducted to obtain costs and 
utilization of antifungal medications and information on species identiﬁcation. Monte 
Carlo simulation models with certain assumptions and limitations were created to 
predict costs. Model inputs were determined based on real-world data. Only antifun-
gal medication costs, incorporating doses, frequencies and 2008 average wholesale 
prices, were considered. One-way and probabilistic sensitivity analyses (2,500 trials) 
were performed. RESULTS: There were 140 candidemic episodes in 132 patients. 
Candida species isolated included albicans (43%), glabrata (29%), parapsilosis (14%), 
tropicalis (6%), krusei (6%), and others. Compared to Test A, median potential cost 
savings per patient are $37 (95% CI $14-$104, Test B) and $51 (95% CI $22-$130, 
Test C). Minimal cost savings per patient are $24 (Test B) and $35 (Test C) at a 
probability of 80%. Two key variables were identiﬁed. Potential cost savings increase 
with increased empiric use of micafungin or decreased prevalence of Candida albicans. 
CONCLUSIONS: With sole consideration of antifungal medication costs, switching 
from Test A to Test C is likely to yield more cost savings than switching to Test B, 
but cost savings may not be substantial.
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OBJECTIVES: Complicated Skin and Skin Structure Infections (cSSSIs) are among 
the most common treated infections in the hospitals. Ceftobiprole has demonstrated 
efﬁcacy in treating cSSSIs in two non-inferiority trials, including those caused by 
methicillin-resistant Staphylococcus aureus (MRSA). It is currently under review 
Abstracts A193
by the FDA for the treatment of cSSSIs. This study investigated the economic implica-
tions of treating cSSSIs with ceftobiprole, compared to vancomycin or ceftazidime. 
METHODS: A discrete event simulation of acute anti-infective treatment in patients 
with cSSSI was developed. Three copies of patients were created. Each copy was 
assigned one of the treatments (ceftobiprole, vancomycin or ceftazidime). Patients’ 
clinical course was simulated using data from clinical trials of ceftobiprole (patient 
and infection characteristics, cure rates, treatment duration, length of hospital 
stay, adverse event rates, treatment discontinuation, use of subsequent treatments). 
Pathogen coverage status was determined based on the extent to which the treatment 
can cover the pathogens causing the infection (MRSA only, Gram-positive non-MRSA, 
Gram-negative, and other possible combinations). Costs in 2007 USD were taken from 
published sources. Various events (relapse, treatment adjustment, and death) and the 
associated direct medical costs were estimated for a treatment episode (49 days). 
Results are based on 100 simulations of 1,000 patients each. RESULTS: The mean 
cost per patient was estimated to be $19,247 treated with ceftobiprole vs. $19,884 
for vancomycin and $19,721 for ceftazidime. The frequencies of cure, relapse, and 
death were similar across the groups. Less than 1% of patients started on ceftobiprole 
required treatment escalation compared to 23% for vancomycin and ceftazidime, 
indicating that ceftobiprole provided broader coverage against the causing pathogens 
of cSSSIs, thus patients received adequate coverage more promptly. CONCLUSIONS: 
Using ceftobiprole for treatment of cSSSIs is expected to provide similar cure rates 
without increasing costs compared to vancomycin and ceftazidime in the US.
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OBJECTIVES: It is common for published models describing the treatment effective-
ness of managing chronic hepatitis C (CHC) to assume those subjects achieving a 
sustained virologic response (SVR) attain a health utility of one; equivalent to perfect 
health. Our objective was to evaluate the impact of utilising age dependent utility 
weights on the cost effectiveness obtained in a CHC model. METHODS: A Markov 
model describing the natural history of CHC in patients with genotype 1 was devel-
oped to estimate the cost effectiveness of treatment with peginterferon α-2a plus 
ribavarin (PEG) versus interferon α-2b plus ribavarin (IFN). The model was popu-
lated with data and validated using a previously published cost effectiveness model. 
The model was re-calibrated using age dependent utility weights for patients achieving 
SVR and run over a lifetime taking a payer perspective, with both costs and beneﬁts 
discounted at 3.5%. RESULTS: The cost per quality adjusted life years (QALYs) 
of PEG versus IFN obtained using age independent SVR disease state utility value 
of one (base case) were: $1713 for those aged 40 years, $3935 for those aged 50 
years, $8612 for those aged 60 years, and $18,485 for those aged 70 years. The 
same analysis performed using age dependent utility values were: $2,373 for those 
aged 40 years, $5,931 for those aged 50 years, $14,924 for those aged 60 years, 
and $46,123 for those aged 70 years. CONCLUSIONS: Health utility is an important 
driver of cost effectiveness in CHC economic models. Compared to the base case, 
age dependent utility weights substantially increase the cost effectiveness ratios, par-
ticularly in patients aged 60 years or over. The assumption that patients attaining 
SVR have perfect health has the potential to bias decision making and there is, 
therefore, a need for future research that better describes the utility proﬁle associated 
with subjects achieving SVR.
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ITALY, SPAIN, AND THE UNITED KINGDOM
Simpson KN1, Dietz B2, Baran RW3, Kirbach SE1, Podsadecki T3
1Medical University of South Carolina, Charleston, SC, USA, 2Abbott GmbH & Co. KG, 
Ludwigshafen, Germany, 3Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: No differences in viral load (VL) or CD4 + T-cell count at 48 weeks 
were reported for the CASTLE study. However, total cholesterol (TC) levels were 
elevated in 7% and 18% of subjects receiving ATV + RTV and LPV/r, respectively. 
These measures can predict outcomes which affect the future cost of HIV in European 
health systems. Our objective was to examine expected CEA and budget impact of 
LPV/r vs. ATV + RTV for patients similar to the CASTLE population, for Germany, 
Italy, Spain, and UK. METHODS: Using a previously published Markov model of 
HIV disease and newly developed cost data, we compared the cost/QALY and budget 
impact of the two ARV regimens. This model used TC levels at 48 weeks and the 
Framingham equation to include effects of heart disease in the model. Costing used 
2009 health services perspective. RESULTS: The CHD risk favored ATV + RTV, 
resulting in a life expectancy increase of 0.031 QALYs (11 days). Cost effectiveness 
ratios for ATV + RTV were: Germany 3239,700; Italy 3178,856; Spain 3200,531; UK 
£125,139 per QALY. Five year per-patient savings were estimated for LPV/r: Germany 
34057; Italy 32681; Spain 33275; UK £1644. If all subjects were assumed to be 
smokers on anti-hypertensive medication, life expectancy improved by 0.088 QALYs 
(32 days) favoring ATV + RTV. However, the ICERs produced under this scenario 
were 396,812/QALY and £65,279/QALY in Germany and UK, respectively. CON-
CLUSIONS: Based on these cost effectiveness ratios, selecting an ATV + RTV based 
regimen in ARV naïve populations with a CHD risk similar to subjects in the CASTLE 
study does not appear to be a cost effective use of scarce resources in any of the 
countries evaluated. Furthermore, costs associated with the very small added CHD 
risk incurred by LPV/r treatment are more than offset by its short and long term cost 
savings.
PIN38
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OBJECTIVES: Analyze and identify total time and cost of recruiting patients into a 
randomized clinical trials(RCT) of Motivational Interviewing-based behavioral inter-
ventions to enhance antiretroviral therapy(ART) adherence. Despite numerous feder-
ally funded RCTs, little literature describes the cost of recruiting patients into 
behavioral interventions to enhance ART adherence. METHODS: A secondary data 
analysis of recruitment data collected for Project MOTIV8(R01 MH68197) was 
conducted. Data from 204 HIV+ patients recruited from the Kansas City metro area 
between June of 2004 and August of 2008 were examined for this cost analysis. Direct 
labor costs for all recruitment staff were collected. Microsoft® Excel spreadsheet was 
used to determine number of attempted recruits, average time spent to recruit/enroll 
a patient, number of successful enrollments, and project resources spent on recruit-
ment. Discounting and sensitivity analysis was done to determine the robustness of 
this cost analysis. RESULTS: Over four years Project MOTIV8 screened 1710 patients 
and successfully enrolled 204 participants (11.9%) into the study. The ratio of patients 
approached to successfully enroll was 8.38:1. Ten minutes was the average time spent 
to recruit a patient, however it required 1.4 hours of effort to enroll an eligible patient 
in the study. All costs are reported in 2008 dollar value. The total cost associated with 
four staff members working on the recruitment effort came to $245,626.70(285 hours) 
over the study period. The cost for attempted recruitment was $143.64(10 minute 
average) and the cost for successful enrollment was $1204.05(1.4 hours) for patients 
with HIV. CONCLUSIONS: The costs associated with recruiting participants into a 
study are often overlooked and underestimated. This economic analysis can serve as 
a guide to determine the budget for actively enrolling patients with speciﬁc risk 
behaviors. This data provides information for understanding ancillary costs and will 
help to shed light on unique challenges in the HIV business environment.
INFECTION – Patient-Reported Outcomes Studies
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OBJECTIVES: The primary purpose of this study was to determine the relationship 
between psychotropic medication use and adherence to combination antiretroviral 
therapy. As a secondary analysis, adherence to combination antiretroviral therapy as 
measured by proportion of days covered (PDC) was compared to adherence based on 
the medication possession ratio (MPR) in order to facilitate comparison between the 
results of this study and those of previous studies evaluating antiretroviral adherence. 
METHODS: Data were extracted from Texas Medicaid ﬁles. Included subjects were 
adults with prescription claims for at least three antiretroviral medications indicated 
for treatment of HIV infection within a 3-month period between 1/1/2004 and 
12/31/2004. PDC was deﬁned as the total number of days during the 12-month follow-
up period for which all index antiretroviral medications were available divided by 365 
days, while MPR was deﬁned as the average number of days supplied for all antiret-
roviral medications divided by 365 days (truncated at 100%). Data were analyzed 
using descriptive statistics. RESULTS: When measured by PDC, the mean adherence 
to combination antiretroviral therapy across the entire sample (N = 1,321) was 39.1% 
± 34.6%. Mean adherence was markedly greater when measured by MPR at 70.4% 
± 33.5%, with a mean difference between the two measures of 31.4% ± 36.8%. 
CONCLUSIONS: PDC provides a more conservative estimate of adherence to com-
bination antiretroviral therapy than MPR. MPR results indicate that adherence in this 
study was similar to that found in previous studies using prescription claims data to 
evaluate adherence to combination antiretroviral therapy using modiﬁed versions of 
the MPR (72–81%). Use of PDC to calculate adherence to combination antiretroviral 
therapy may provide more clinically relevant information than other measures since 
concomitant use of all medications in the regimen is theoretically required for syner-
gistic viral suppression and optimal HIV outcomes.
